Sept 16, 2010 - Clinical study confirms new features of S9 Series prolong patients' sleep by up to 30 minutes - ResMed (NYSE: RMD), a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment announced the results of a clinical study confirming that patients' compliance with sleep therapy increases when using ResMed's new CPAP device.The clinical study of 50 patients suffering from sleep apnoea showed an improvement of 30 minutes in average daily usage, from a mean of 6 hours 35 minutes on the patient's usual CPAP device, to 7 hours 5 minutes, when using the new S9 Series.
Sleep apnoea is one of the more common, and yet highly undiagnosed, sleep disorders. Obstructive sleep apnoea (OSA) is the most common type of sleep apnoea and is marked by the collapse or obstruction of the airway during sleep. The most effective treatment is Continuous Positive Airway Pressure (CPAP) therapy. In this non-invasive treatment, air is pressurised by a small device and delivered to the airway of the patient through a mask that fits on/over the nose, or nose and mouth. The pressurised air keeps the upper airway open and helps the person to get a restful night without interruptions caused by apnoeas... ResMed's Press Release -
